Skip to content
Evigrade
CriticalAntidepressants. Other antidepressants of herbal origin×Reversible MAO-A inhibitor (RIMA)

Updated · Methodology

Mechanism

Moclobemide reversibly inhibits monoamine oxidase type A and slows the breakdown of serotonin, noradrenaline and dopamine (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). St John's wort extract inhibits the synaptosomal reuptake of the same neurotransmitters (St John's wort SmPC, AEMPS, section 5.1), and according to the moclobemide SmPC it may raise serotonin levels in the central nervous system (moclobemide SmPC, AEMPS, section 4.5). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with moclobemide (St John's wort SmPC, AEMPS, section 4.5). CYP2C19 and CYP2D6 partly metabolise moclobemide (moclobemide SmPC, AEMPS, section 5.2), and hyperforin in St John's wort induces CYP2C19 (St John's wort SmPC, AEMPS, section 5.2). The documents give no data on how this changes moclobemide levels.

Symptoms

The main risk is serotonin syndrome. According to the European Medicines Agency (EMA) herbal monograph, it occurs very rarely with serotonergic substances and presents with sweating, tachycardia, diarrhoea, fever, agitation, disorientation, tremor and myoclonus (St John's wort herbal monograph, EMA, section 4.5). The moclobemide summary of product characteristics (SmPC) reports isolated severe cases with other medicines that raise serotonin: hyperthermia, confusion, hyperreflexia and myoclonus (moclobemide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Overall, the syndrome can involve mental status changes, autonomic instability, neuromuscular abnormalities and gastrointestinal symptoms (moclobemide SmPC, AEMPS, section 4.4).

Management

The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, including monoamine oxidase inhibitors (MAOIs), and its interaction table names moclobemide (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The moclobemide SmPC also does not recommend use with St John's wort (moclobemide SmPC, AEMPS, section 4.5). If the two have nevertheless been taken together and hyperthermia, confusion, hyperreflexia and myoclonus appear, keep the patient under medical observation, in hospital if needed, and start treatment (moclobemide SmPC, AEMPS, section 4.5). If serotonin syndrome is suspected, consider reducing the dose or stopping treatment, depending on severity (moclobemide SmPC, AEMPS, section 4.4). Another antidepressant may be started the day after moclobemide is stopped (moclobemide SmPC, AEMPS, section 4.5), and its own SmPC places St John's wort in the group of other antidepressants (St John's wort SmPC, AEMPS, section 5.1). No document says how long to wait when switching from St John's wort to moclobemide.

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Hypericum perforatum

Other interactions with Moclobemide